奥沙利铂和伊立替康联合贝伐珠单抗治疗术后复发性大肠癌的疗效评价  

Clinical evaluation of oxaliplatin and irinotecan combined with bevacizumab in the treatment of postoperative recurrent colorectal cancer

作　　者：周明利 王春明[2] ZHOU Mingli;WANG Chunming(Department of General Surgery,Wuxi Fifth People’s Hospital,Wuxi,Jiangsu 214000,China;Department of General Surgery,Wuxi Second People’s Hospital,Wuxi,Jiangsu 214000,China)

机构地区：[1]无锡市第五人民医院普外科,江苏无锡214000 [2]无锡市第二人民医院普外科,江苏无锡214000

出　　处：《安徽医药》2020年第10期2090-2094,共5页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探讨奥沙利铂和伊立替康联合贝伐珠单抗对术后复发性大肠癌合并腹腔转移病人的临床疗效。方法将80例病人(无锡市第二人民医院2013年3月至2016年3月的复发性大肠癌病人)按随机数字表法分为对照组(奥沙利铂和伊立替康组)与观察组(奥沙利铂和伊立替康联合贝伐珠单抗组进行化疗),每组各40例,对比两组病人治疗前后血清肿瘤标志物的水平变化,观察并比较分析两组病人临床化疗效果、生存时间及不良反应发生情况。结果观察组化疗前后测得血清肿瘤标记物水平差异明显高于对照组,差异有统计学意义(P<0.05)。化疗后,观察组总有效率(RR)与疾病控制率(DCR)(60.00%,90.00%)明显高于对照组(37.50%,65.00%)(P<0.05)。观察组不良反应发病率稍高于对照组(P>0.05)。74例化疗后随访,观察组生存率及平均生存时间(19.5±3.1)月明显长于对照组(10.5±4.9)月(P<0.05)。结论贝伐珠单抗联合奥沙利铂和伊立替康的化疗方案用于治疗术后复发性大肠癌,能够较好地缓解和控制病情,延长病人生存时间,且并未加重病人化疗的不良反应。Objective To investigate the clinical efficacy of oxaliplatin and irinotecan combined with bevacizumab in the treatment of postoperative recurrent colorectal cancer with peritoneal metastasis.Methods Eighty patientswith recurrent colorectal cancer in Wuxi Second Hospital from March 2013 to March 2016 were divided into the control group(oxaliplatin and irinotecan group,n=40)and the observation group(oxaliplatin and irinotecan combined with bevacizumab group,n=40)for chemotherapy.The changes of serum tumor markers before and after treatment,the clinical effects of chemotherapy,survival time and adverse reactions were observed and compared between the two groups.ResultsThe difference of serum tumor markers before and after chemotherapy in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After chemotherapy,the total effective rate(RR)and disease control rate(DCR)of the observation group(60.00%,90.00%)were significantly higher than those of the control group(37.50%,65.00%),and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was slightly higher than that in the control group,with no statistically significant difference(P>0.05).74 cases Follow-up after chemotherapy showed that the survival rate and average survival time of the observation group(19.5±3.1 months)were significantly longer than that of the control group(10.5±4.9 months),and the difference was statistically significant(P<0.05).ConclusionThe chemotherapy regimen of bevacizumab combined with oxaliplatin and Irinotecan in the treatment recurrent colorectal cancer after surgery can better alleviate and control patients’condition,improve their quality of life and prolong their survival time without aggravating the adverse reactions of chemotherapy.

关 键 词：结直肠肿瘤/治疗 奥沙利铂 伊立替康 复发 治疗结果 贝伐珠单抗 

分 类 号：R735.34[医药卫生—肿瘤]